Share Price and Basic Stock Data
Last Updated: November 19, 2025, 9:18 pm
| PEG Ratio | -6.50 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Hikal Ltd operates in the pharmaceuticals sector, where it reported a market capitalization of ₹2,820 Cr and a stock price of ₹229. The company has shown fluctuating revenue trends, with total sales of ₹2,023 Cr for FY 2023, a slight increase from ₹1,943 Cr in FY 2022. However, the revenue has been projected to decline to ₹1,785 Cr in FY 2024 before recovering to ₹1,860 Cr in FY 2025. Quarterly sales data indicates variability, with the highest quarterly sales recorded at ₹559 Cr in September 2022 and the lowest at ₹379 Cr in June 2022. Notably, the trailing twelve months (TTM) revenue stands at ₹1,699 Cr, reflecting a downward trend compared to the previous years. The company’s operational performance is further evidenced by its operating margin (OPM), which has fluctuated from 16% in March 2023 to an expected 18% in March 2025, indicating potential improvement in operational efficiency. Overall, while the revenue growth trajectory shows volatility, the company is focusing on operational improvements to stabilize its financial performance.
Profitability and Efficiency Metrics
Hikal Ltd’s profitability metrics reveal a mixed performance, with a net profit of ₹78 Cr reported for FY 2023, down from ₹160 Cr in FY 2022. The net profit margin also declined to 3.87% in FY 2023 from 8.26% in FY 2022, reflecting the challenges in maintaining profitability amidst fluctuating sales. The company reported an impressive operating profit of ₹341 Cr for FY 2022, which decreased to ₹258 Cr in FY 2023, resulting in an operating profit margin of 13%. Efficiency ratios such as the return on equity (ROE) stood at 7.19% for FY 2025, which is below the industry average, indicating that the company is not generating sufficient returns on its equity base. Additionally, the cash conversion cycle (CCC) is reported at 116 days, which is relatively high and suggests inefficiencies in managing working capital. While Hikal Ltd has the potential to improve its operational efficiencies, the current profitability and efficiency metrics indicate areas that require focused management intervention.
Balance Sheet Strength and Financial Ratios
Hikal Ltd’s balance sheet reflects a total asset base of ₹2,529 Cr as of March 2025, with total liabilities amounting to ₹2,529 Cr, indicating a balanced financial structure. The company’s reserves have risen to ₹1,238 Cr, showcasing a strong equity position. However, borrowings also increased to ₹765 Cr, leading to a total debt-to-equity ratio of 0.60, which is within a manageable range but could pose risks if debt levels continue to rise. The interest coverage ratio (ICR) is reported at 4.43x, suggesting that the company can comfortably meet its interest obligations. The return on capital employed (ROCE) is reported at 11.44%, indicating a moderate efficiency in utilizing capital for generating profits. Comparatively, Hikal’s price-to-book value (P/BV) ratio stands at 3.91x, suggesting that the stock may be overvalued relative to its book value. Overall, while Hikal Ltd maintains a reasonable capital structure and liquidity ratios, the increasing debt levels and moderate returns on capital employed are areas to monitor closely.
Shareholding Pattern and Investor Confidence
Hikal Ltd’s shareholding structure is predominantly controlled by promoters, who hold 68.85% of the equity, reflecting strong management control and commitment to the company. Institutional investors, including foreign institutional investors (FIIs) and domestic institutional investors (DIIs), hold 4.23% and 5.15% of the shares, respectively. The gradual increase in FIIs from 4.40% in December 2022 to a peak of 6.14% in December 2023 indicates growing confidence among foreign investors. Conversely, the public shareholding has seen a decline from 25.20% in December 2022 to 21.75% in March 2025. The overall number of shareholders has also decreased to 73,404, suggesting a potential consolidation of shareholder interest. The stability in promoter holdings combined with fluctuating institutional interest points to a mixed sentiment among investors. The strong promoter backing is a positive sign; however, the declining public shareholding may raise concerns about broader market confidence.
Outlook, Risks, and Final Insight
The outlook for Hikal Ltd hinges on its ability to stabilize revenue and improve profitability amidst a competitive pharmaceutical landscape. Key strengths include a solid promoter backing, a robust reserve position, and improving operational efficiency metrics. However, risks encompass declining profitability margins, increasing debt levels, and a high cash conversion cycle that may hinder liquidity. The company’s ability to navigate regulatory challenges and adapt to market dynamics will be crucial for future performance. Should Hikal Ltd successfully implement cost-control measures and enhance operational efficiencies, it could return to a growth trajectory. Conversely, failure to address the highlighted risks may lead to further decline in profitability and shareholder sentiment. Investors should remain vigilant about the company’s strategic initiatives and market positioning as it strives for recovery and growth.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Hikal Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 159 Cr. | 127 | 247/84.3 | 35.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,768 Cr. | 438 | 479/192 | 98.7 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.0 Cr. | 43.1 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 38.7 Cr. | 26.4 | 29.1/17.0 | 92.1 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,252.29 Cr | 1,184.24 | 53.13 | 202.47 | 0.35% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 379 | 559 | 540 | 545 | 388 | 435 | 448 | 514 | 407 | 453 | 448 | 552 | 380 |
| Expenses | 356 | 489 | 466 | 457 | 338 | 377 | 383 | 420 | 349 | 378 | 376 | 429 | 355 |
| Operating Profit | 23 | 70 | 75 | 88 | 50 | 58 | 65 | 94 | 58 | 75 | 72 | 123 | 25 |
| OPM % | 6% | 12% | 14% | 16% | 13% | 13% | 14% | 18% | 14% | 17% | 16% | 22% | 7% |
| Other Income | 3 | 1 | 3 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 4 | 0 | 1 |
| Interest | 11 | 11 | 13 | 13 | 14 | 13 | 14 | 15 | 20 | 19 | 19 | 18 | 17 |
| Depreciation | 26 | 27 | 28 | 27 | 28 | 29 | 29 | 32 | 32 | 32 | 33 | 38 | 39 |
| Profit before tax | -12 | 33 | 36 | 49 | 10 | 17 | 22 | 47 | 7 | 25 | 24 | 68 | -30 |
| Tax % | -25% | 24% | 26% | 26% | 29% | 25% | 25% | 28% | 26% | 26% | 28% | 26% | -26% |
| Net Profit | -9 | 25 | 26 | 36 | 7 | 13 | 16 | 34 | 5 | 18 | 17 | 50 | -22 |
| EPS in Rs | -0.72 | 2.01 | 2.14 | 2.92 | 0.56 | 1.02 | 1.31 | 2.75 | 0.41 | 1.48 | 1.39 | 4.07 | -1.82 |
Last Updated: August 20, 2025, 9:40 am
Below is a detailed analysis of the quarterly data for Hikal Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 380.00 Cr.. The value appears to be declining and may need further review. It has decreased from 552.00 Cr. (Mar 2025) to 380.00 Cr., marking a decrease of 172.00 Cr..
- For Expenses, as of Jun 2025, the value is 355.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 429.00 Cr. (Mar 2025) to 355.00 Cr., marking a decrease of 74.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 25.00 Cr.. The value appears to be declining and may need further review. It has decreased from 123.00 Cr. (Mar 2025) to 25.00 Cr., marking a decrease of 98.00 Cr..
- For OPM %, as of Jun 2025, the value is 7.00%. The value appears to be declining and may need further review. It has decreased from 22.00% (Mar 2025) to 7.00%, marking a decrease of 15.00%.
- For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 17.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 18.00 Cr. (Mar 2025) to 17.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 39.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 38.00 Cr. (Mar 2025) to 39.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -30.00 Cr.. The value appears to be declining and may need further review. It has decreased from 68.00 Cr. (Mar 2025) to -30.00 Cr., marking a decrease of 98.00 Cr..
- For Tax %, as of Jun 2025, the value is -26.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Mar 2025) to -26.00%, marking a decrease of 52.00%.
- For Net Profit, as of Jun 2025, the value is -22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 50.00 Cr. (Mar 2025) to -22.00 Cr., marking a decrease of 72.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -1.82. The value appears to be declining and may need further review. It has decreased from 4.07 (Mar 2025) to -1.82, marking a decrease of 5.89.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 5:15 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 829 | 872 | 926 | 1,014 | 1,296 | 1,590 | 1,507 | 1,720 | 1,943 | 2,023 | 1,785 | 1,860 | 1,699 |
| Expenses | 642 | 689 | 745 | 813 | 1,054 | 1,291 | 1,234 | 1,398 | 1,602 | 1,765 | 1,518 | 1,531 | 1,471 |
| Operating Profit | 187 | 182 | 181 | 201 | 242 | 298 | 273 | 323 | 341 | 258 | 267 | 328 | 228 |
| OPM % | 23% | 21% | 20% | 20% | 19% | 19% | 18% | 19% | 18% | 13% | 15% | 18% | 13% |
| Other Income | 34 | 2 | 2 | -3 | 4 | 2 | -12 | 5 | 5 | 5 | 2 | 5 | 7 |
| Interest | 68 | 60 | 62 | 48 | 49 | 58 | 52 | 36 | 31 | 48 | 56 | 75 | 69 |
| Depreciation | 55 | 64 | 67 | 69 | 86 | 93 | 82 | 85 | 96 | 109 | 118 | 134 | 152 |
| Profit before tax | 98 | 60 | 53 | 80 | 112 | 149 | 127 | 206 | 219 | 105 | 96 | 124 | 15 |
| Tax % | 35% | 32% | 23% | 16% | 31% | 31% | 33% | 36% | 27% | 26% | 27% | 27% | |
| Net Profit | 64 | 40 | 41 | 68 | 77 | 103 | 84 | 133 | 160 | 78 | 70 | 91 | 10 |
| EPS in Rs | 5.17 | 3.28 | 3.34 | 5.49 | 6.26 | 8.36 | 6.85 | 10.80 | 13.02 | 6.36 | 5.64 | 7.36 | 0.81 |
| Dividend Payout % | 12% | 20% | 20% | 15% | 13% | 14% | 18% | 19% | 12% | 19% | 21% | 11% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -37.50% | 2.50% | 65.85% | 13.24% | 33.77% | -18.45% | 58.33% | 20.30% | -51.25% | -10.26% | 30.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 40.00% | 63.35% | -52.62% | 20.53% | -52.21% | 76.78% | -38.03% | -71.55% | 40.99% | 40.26% |
Hikal Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 4% |
| 3 Years: | -1% |
| TTM: | 2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | -1% |
| 3 Years: | -17% |
| TTM: | -6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 10% |
| 3 Years: | -8% |
| 1 Year: | -26% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 10% |
| 3 Years: | 7% |
| Last Year: | 7% |
Last Updated: September 5, 2025, 6:05 am
Balance Sheet
Last Updated: June 16, 2025, 12:01 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 16 | 16 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
| Reserves | 488 | 516 | 547 | 589 | 653 | 732 | 792 | 909 | 1,043 | 1,109 | 1,163 | 1,238 |
| Borrowings | 546 | 547 | 505 | 598 | 635 | 661 | 646 | 610 | 675 | 748 | 818 | 765 |
| Other Liabilities | 219 | 212 | 206 | 177 | 237 | 268 | 306 | 370 | 470 | 504 | 482 | 502 |
| Total Liabilities | 1,270 | 1,292 | 1,275 | 1,379 | 1,542 | 1,686 | 1,768 | 1,913 | 2,213 | 2,385 | 2,487 | 2,529 |
| Fixed Assets | 644 | 639 | 623 | 668 | 634 | 713 | 735 | 713 | 879 | 948 | 1,071 | 1,364 |
| CWIP | 61 | 62 | 66 | 63 | 118 | 79 | 161 | 254 | 295 | 412 | 414 | 121 |
| Investments | 3 | 3 | 3 | 4 | 3 | 1 | 1 | 1 | 11 | 5 | 5 | 10 |
| Other Assets | 562 | 588 | 583 | 645 | 788 | 893 | 871 | 946 | 1,028 | 1,020 | 997 | 1,034 |
| Total Assets | 1,270 | 1,292 | 1,275 | 1,379 | 1,542 | 1,686 | 1,768 | 1,913 | 2,213 | 2,385 | 2,487 | 2,529 |
Below is a detailed analysis of the balance sheet data for Hikal Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 25.00 Cr..
- For Reserves, as of Mar 2025, the value is 1,238.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,163.00 Cr. (Mar 2024) to 1,238.00 Cr., marking an increase of 75.00 Cr..
- For Borrowings, as of Mar 2025, the value is 765.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 818.00 Cr. (Mar 2024) to 765.00 Cr., marking a decrease of 53.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 502.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 482.00 Cr. (Mar 2024) to 502.00 Cr., marking an increase of 20.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 2,529.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,487.00 Cr. (Mar 2024) to 2,529.00 Cr., marking an increase of 42.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 1,364.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,071.00 Cr. (Mar 2024) to 1,364.00 Cr., marking an increase of 293.00 Cr..
- For CWIP, as of Mar 2025, the value is 121.00 Cr.. The value appears to be declining and may need further review. It has decreased from 414.00 Cr. (Mar 2024) to 121.00 Cr., marking a decrease of 293.00 Cr..
- For Investments, as of Mar 2025, the value is 10.00 Cr.. The value appears strong and on an upward trend. It has increased from 5.00 Cr. (Mar 2024) to 10.00 Cr., marking an increase of 5.00 Cr..
- For Other Assets, as of Mar 2025, the value is 1,034.00 Cr.. The value appears strong and on an upward trend. It has increased from 997.00 Cr. (Mar 2024) to 1,034.00 Cr., marking an increase of 37.00 Cr..
- For Total Assets, as of Mar 2025, the value is 2,529.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,487.00 Cr. (Mar 2024) to 2,529.00 Cr., marking an increase of 42.00 Cr..
Notably, the Reserves (1,238.00 Cr.) exceed the Borrowings (765.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -359.00 | -365.00 | -324.00 | -397.00 | -393.00 | -363.00 | -373.00 | -287.00 | -334.00 | -490.00 | -551.00 | -437.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 39 | 54 | 44 | 92 | 81 | 80 | 82 | 103 | 82 | 80 | 113 | 103 |
| Inventory Days | 302 | 268 | 229 | 189 | 158 | 156 | 147 | 107 | 121 | 104 | 134 | 146 |
| Days Payable | 127 | 117 | 101 | 93 | 86 | 68 | 95 | 92 | 91 | 103 | 123 | 133 |
| Cash Conversion Cycle | 214 | 205 | 173 | 188 | 153 | 168 | 135 | 118 | 112 | 81 | 124 | 116 |
| Working Capital Days | 0 | -13 | 29 | 43 | 29 | 45 | 28 | 39 | 26 | 39 | 39 | 37 |
| ROCE % | 16% | 11% | 11% | 12% | 13% | 15% | 14% | 16% | 15% | 8% | 8% | 10% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal Nifty Microcap 250 Index Fund | 36,683 | 0.22 | 1.01 | 36,683 | 2025-04-22 17:25:33 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 405 | 0.14 | 0.01 | 405 | 2025-04-22 17:25:33 | 0% |
| Groww Nifty Total Market Index Fund | 85 | 0.01 | 0 | 85 | 2025-04-22 17:25:33 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 7.36 | 5.64 | 6.36 | 13.02 | 10.80 |
| Diluted EPS (Rs.) | 7.36 | 5.64 | 6.36 | 13.02 | 10.80 |
| Cash EPS (Rs.) | 18.23 | 15.18 | 15.20 | 20.78 | 17.71 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 102.21 | 96.32 | 91.93 | 86.62 | 75.70 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 102.21 | 96.32 | 91.93 | 86.62 | 75.70 |
| Revenue From Operations / Share (Rs.) | 150.59 | 144.74 | 164.07 | 157.56 | 139.53 |
| PBDIT / Share (Rs.) | 27.00 | 21.86 | 21.29 | 28.02 | 26.59 |
| PBIT / Share (Rs.) | 16.11 | 12.32 | 12.45 | 20.26 | 19.68 |
| PBT / Share (Rs.) | 10.02 | 7.75 | 8.55 | 17.73 | 16.74 |
| Net Profit / Share (Rs.) | 7.35 | 5.64 | 6.36 | 13.02 | 10.80 |
| NP After MI And SOA / Share (Rs.) | 7.35 | 5.64 | 6.36 | 13.02 | 10.80 |
| PBDIT Margin (%) | 17.92 | 15.10 | 12.97 | 17.78 | 19.05 |
| PBIT Margin (%) | 10.70 | 8.51 | 7.58 | 12.85 | 14.10 |
| PBT Margin (%) | 6.65 | 5.35 | 5.20 | 11.25 | 11.99 |
| Net Profit Margin (%) | 4.88 | 3.90 | 3.87 | 8.26 | 7.73 |
| NP After MI And SOA Margin (%) | 4.88 | 3.90 | 3.87 | 8.26 | 7.73 |
| Return on Networth / Equity (%) | 7.19 | 5.86 | 6.91 | 15.02 | 14.26 |
| Return on Capital Employeed (%) | 11.44 | 8.77 | 8.90 | 17.29 | 19.31 |
| Return On Assets (%) | 3.59 | 2.79 | 3.28 | 7.25 | 6.95 |
| Long Term Debt / Equity (X) | 0.29 | 0.35 | 0.43 | 0.26 | 0.28 |
| Total Debt / Equity (X) | 0.60 | 0.68 | 0.65 | 0.63 | 0.55 |
| Asset Turnover Ratio (%) | 0.74 | 0.73 | 0.87 | 0.94 | 0.93 |
| Current Ratio (X) | 1.26 | 1.28 | 1.42 | 1.25 | 1.34 |
| Quick Ratio (X) | 0.83 | 0.87 | 0.94 | 0.82 | 0.93 |
| Inventory Turnover Ratio (X) | 5.83 | 2.60 | 3.47 | 3.47 | 3.13 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 21.25 | 15.73 | 16.90 | 11.11 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 7.90 | 6.57 | 10.58 | 6.77 |
| Earning Retention Ratio (%) | 0.00 | 78.75 | 84.27 | 83.10 | 88.89 |
| Cash Earning Retention Ratio (%) | 0.00 | 92.10 | 93.43 | 89.42 | 93.23 |
| Interest Coverage Ratio (X) | 4.43 | 4.78 | 5.46 | 11.07 | 9.06 |
| Interest Coverage Ratio (Post Tax) (X) | 2.21 | 2.23 | 2.63 | 6.14 | 4.68 |
| Enterprise Value (Cr.) | 5685.34 | 4058.84 | 4164.23 | 5587.56 | 2246.86 |
| EV / Net Operating Revenue (X) | 3.06 | 2.27 | 2.06 | 2.88 | 1.31 |
| EV / EBITDA (X) | 17.05 | 15.06 | 15.87 | 16.17 | 6.85 |
| MarketCap / Net Operating Revenue (X) | 2.66 | 1.83 | 1.72 | 2.55 | 1.03 |
| Retention Ratios (%) | 0.00 | 78.74 | 84.26 | 83.09 | 88.88 |
| Price / BV (X) | 3.91 | 2.75 | 3.07 | 4.65 | 1.90 |
| Price / Net Operating Revenue (X) | 2.66 | 1.83 | 1.72 | 2.55 | 1.03 |
| EarningsYield | 0.01 | 0.02 | 0.02 | 0.03 | 0.07 |
After reviewing the key financial ratios for Hikal Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 7.36. This value is within the healthy range. It has increased from 5.64 (Mar 24) to 7.36, marking an increase of 1.72.
- For Diluted EPS (Rs.), as of Mar 25, the value is 7.36. This value is within the healthy range. It has increased from 5.64 (Mar 24) to 7.36, marking an increase of 1.72.
- For Cash EPS (Rs.), as of Mar 25, the value is 18.23. This value is within the healthy range. It has increased from 15.18 (Mar 24) to 18.23, marking an increase of 3.05.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 102.21. It has increased from 96.32 (Mar 24) to 102.21, marking an increase of 5.89.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 102.21. It has increased from 96.32 (Mar 24) to 102.21, marking an increase of 5.89.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 150.59. It has increased from 144.74 (Mar 24) to 150.59, marking an increase of 5.85.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 27.00. This value is within the healthy range. It has increased from 21.86 (Mar 24) to 27.00, marking an increase of 5.14.
- For PBIT / Share (Rs.), as of Mar 25, the value is 16.11. This value is within the healthy range. It has increased from 12.32 (Mar 24) to 16.11, marking an increase of 3.79.
- For PBT / Share (Rs.), as of Mar 25, the value is 10.02. This value is within the healthy range. It has increased from 7.75 (Mar 24) to 10.02, marking an increase of 2.27.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 7.35. This value is within the healthy range. It has increased from 5.64 (Mar 24) to 7.35, marking an increase of 1.71.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 7.35. This value is within the healthy range. It has increased from 5.64 (Mar 24) to 7.35, marking an increase of 1.71.
- For PBDIT Margin (%), as of Mar 25, the value is 17.92. This value is within the healthy range. It has increased from 15.10 (Mar 24) to 17.92, marking an increase of 2.82.
- For PBIT Margin (%), as of Mar 25, the value is 10.70. This value is within the healthy range. It has increased from 8.51 (Mar 24) to 10.70, marking an increase of 2.19.
- For PBT Margin (%), as of Mar 25, the value is 6.65. This value is below the healthy minimum of 10. It has increased from 5.35 (Mar 24) to 6.65, marking an increase of 1.30.
- For Net Profit Margin (%), as of Mar 25, the value is 4.88. This value is below the healthy minimum of 5. It has increased from 3.90 (Mar 24) to 4.88, marking an increase of 0.98.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 4.88. This value is below the healthy minimum of 8. It has increased from 3.90 (Mar 24) to 4.88, marking an increase of 0.98.
- For Return on Networth / Equity (%), as of Mar 25, the value is 7.19. This value is below the healthy minimum of 15. It has increased from 5.86 (Mar 24) to 7.19, marking an increase of 1.33.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.44. This value is within the healthy range. It has increased from 8.77 (Mar 24) to 11.44, marking an increase of 2.67.
- For Return On Assets (%), as of Mar 25, the value is 3.59. This value is below the healthy minimum of 5. It has increased from 2.79 (Mar 24) to 3.59, marking an increase of 0.80.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.29. This value is within the healthy range. It has decreased from 0.35 (Mar 24) to 0.29, marking a decrease of 0.06.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.60. This value is within the healthy range. It has decreased from 0.68 (Mar 24) to 0.60, marking a decrease of 0.08.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.74. It has increased from 0.73 (Mar 24) to 0.74, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 1.26. This value is below the healthy minimum of 1.5. It has decreased from 1.28 (Mar 24) to 1.26, marking a decrease of 0.02.
- For Quick Ratio (X), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 1. It has decreased from 0.87 (Mar 24) to 0.83, marking a decrease of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.83. This value is within the healthy range. It has increased from 2.60 (Mar 24) to 5.83, marking an increase of 3.23.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 21.25 (Mar 24) to 0.00, marking a decrease of 21.25.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 7.90 (Mar 24) to 0.00, marking a decrease of 7.90.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 78.75 (Mar 24) to 0.00, marking a decrease of 78.75.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 92.10 (Mar 24) to 0.00, marking a decrease of 92.10.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.43. This value is within the healthy range. It has decreased from 4.78 (Mar 24) to 4.43, marking a decrease of 0.35.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.21. This value is below the healthy minimum of 3. It has decreased from 2.23 (Mar 24) to 2.21, marking a decrease of 0.02.
- For Enterprise Value (Cr.), as of Mar 25, the value is 5,685.34. It has increased from 4,058.84 (Mar 24) to 5,685.34, marking an increase of 1,626.50.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.06. This value exceeds the healthy maximum of 3. It has increased from 2.27 (Mar 24) to 3.06, marking an increase of 0.79.
- For EV / EBITDA (X), as of Mar 25, the value is 17.05. This value exceeds the healthy maximum of 15. It has increased from 15.06 (Mar 24) to 17.05, marking an increase of 1.99.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.66. This value is within the healthy range. It has increased from 1.83 (Mar 24) to 2.66, marking an increase of 0.83.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 78.74 (Mar 24) to 0.00, marking a decrease of 78.74.
- For Price / BV (X), as of Mar 25, the value is 3.91. This value exceeds the healthy maximum of 3. It has increased from 2.75 (Mar 24) to 3.91, marking an increase of 1.16.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.66. This value is within the healthy range. It has increased from 1.83 (Mar 24) to 2.66, marking an increase of 0.83.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Hikal Ltd:
- Net Profit Margin: 4.88%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.44% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 7.19% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.21
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.83
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 277 (Industry average Stock P/E: 53.13)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.6
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.88%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 717/718, Maker Chambers V, Mumbai Maharashtra 400021 | info@hikal.com http://www.hikal.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Jai Hiremath | Executive Chairman |
| Mr. Sameer Hiremath | Vice Chairman & Mng.Director |
| Mr. Sarangan Suresh | Whole Time Director |
| Ms. Sugandha Hiremath | Non Executive Director |
| Mr. Amit Kalyani | Non Executive Director |
| Mrs. Shivani Bhasin Sachdeva | Ind. Non-Executive Director |
| Mr. Shrikrishna Adivarekar | Ind. Non-Executive Director |
| Mr. Ramachandra Kaundinya | Ind. Non-Executive Director |
| Mr. Berjis Desai | Ind. Non-Executive Director |
| Mr. Ravi Kapoor | Ind. Non-Executive Director |
| Mr. Ranjana S Salgaocar | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Hikal Ltd?
Hikal Ltd's intrinsic value (as of 19 November 2025) is 1594.54 which is 602.44% higher the current market price of 227.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 2,800 Cr. market cap, FY2025-2026 high/low of 465/225, reserves of ₹1,238 Cr, and liabilities of 2,529 Cr.
What is the Market Cap of Hikal Ltd?
The Market Cap of Hikal Ltd is 2,800 Cr..
What is the current Stock Price of Hikal Ltd as on 19 November 2025?
The current stock price of Hikal Ltd as on 19 November 2025 is 227.
What is the High / Low of Hikal Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Hikal Ltd stocks is 465/225.
What is the Stock P/E of Hikal Ltd?
The Stock P/E of Hikal Ltd is 277.
What is the Book Value of Hikal Ltd?
The Book Value of Hikal Ltd is 96.9.
What is the Dividend Yield of Hikal Ltd?
The Dividend Yield of Hikal Ltd is 0.62 %.
What is the ROCE of Hikal Ltd?
The ROCE of Hikal Ltd is 9.85 %.
What is the ROE of Hikal Ltd?
The ROE of Hikal Ltd is 7.38 %.
What is the Face Value of Hikal Ltd?
The Face Value of Hikal Ltd is 2.00.